DBV Technologies | DBVT - Cash And Equivalent


DBV Technologies reported $69.84M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Galectin Therapeutics USD 25.6M 2.04M Jun/2024
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Incyte USD 3.58B 650.78M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
United Therapeutics USD 1.56B 217M Dec/2025